

PRESENTING THE 2ND ANNUAL

# Bio Connections Australia

Optimising Clinical Trials | Commercialising Great Science | Partnering for Growth

19 – 20 August 2019 | Pullman Melbourne Albert Park

### INTERNATIONAL KEYNOTES INCLUDE:



Jin-San Yoo  
President & CEO,  
PharmAbcine, Inc,  
South Korea



Vishal Doshi  
CEO,  
AUM Biosciences,  
Singapore



Jeremy Yee  
Executive Director & CEO,  
Clearbridge Health  
Limited, Singapore



Juran Kato  
President and CEO,  
GEXVal Inc, Japan



Xiaowei Shi  
Executive Director,  
Clinical Operations, Asia-  
Pacific, BeiGene, China

### FEATURED SPEAKERS INCLUDE:



Avi Rebera, Assistant  
Secretary, Regulatory  
Engagement & Planning  
Branch, Department of  
Health (TGA)



Chevlin Lee  
Managing Principal,  
Chalten Capital



Mark Sullivan  
2019 VIC Australian of  
the Year and Managing  
Director, Medicines  
Development for Global  
Health



Sam Cobb  
Managing Director &  
CEO, AdAlta



Bill Ketelby  
CEO, Actinogen



Sarah Meibusch  
Principal,  
One Ventures



Chris Nave  
Managing Director,  
Melbourne,  
Brandon Capital  
Partners



Megan Baldwin  
Managing Director &  
CEO, Opthea



Dr Thomas Oxley  
CEO and Founder,  
Synchron



Leslie Chong  
MD & CEO, Imugene




Dr Anand Gautam  
Senior Director & Head  
of Asia Discovery lab & CTI  
Emerging Science &  
Innovation, Pfizer



Kathy Harrison  
Head of IP Strategy,  
ProTA Therapeutics

### SUPPORTING SPONSORS & EXHIBITORS:



REGISTER NOW [www.informa.com.au/bioconnections2019](http://www.informa.com.au/bioconnections2019)




8:30 Morning Coffee on Arrival

8:50 **OPENING | Opening remarks from the Chair**

Tam C. Nguyen, *Deputy Director Research, St Vincent's Hospital Melbourne*

9:00 **INTERNATIONAL KEYNOTE | An Asia to Global Strategy for Success**


 Vishal Doshi, *CEO, AUM Biosciences, Singapore*

9:30 **INTERNATIONAL KEYNOTE | Clinical Development of PharmAbcine in Australia and its Perspective**


 Jin-San Yoo, *President & CEO, PharmAbcine, Inc, South Korea*

10:00 **INTERNATIONAL PANEL | Experiences, Pros & Cons of Doing Trials in Australia**

- International biotechs share their thinking and motivations for doing trials in Australia
- Reservations about Australia vs elsewhere?
- What are the ultimate drivers for decision making on where to do early phase trials?
- Experiences and challenges faced

 Jin-San Yoo, *President & CEO, PharmAbcine, Inc, South Korea*

 Jeremy Yee, *Executive Director & CEO, Clearbridge Health Limited, Singapore*

 Vishal Doshi, *CEO, AUM Biosciences, Singapore*

 Xiaowei Shi, *Executive Director, Clinical Operations, Asia-Pacific, BeiGene, China*

10:40 Networking Coffee Break

11:10 **Medicines Development for Global Health**

Mark Sullivan, *2019 VIC Australian of the Year and Managing Director, Medicines Development for Global Health*

11:40 **Planning a Global Trial and How to Choose Your Program**

Bill Ketelby, *CEO, Actinogen*

12:10 **PANEL | Making Trials in Australia More Meaningful: Designing A Clinical Trial Program for Commercialisation**

- What do we mean by meaningful trials and what are the motivations for different stakeholders?
- What do partners expect from clinical trials?
- Designing studies that will give you the best end result
- What is needed for phase I, phase II & phase III studies?
- Designing clinical trial programme with an exit strategy
- How to drive efficiency in clinical trial development to accelerate commercialization
- How can companies attract investment and partners with a strong clinical development program?

Erin Mistry, *Managing Director Value and Access, Syneos Health*

Dr Anand Gautam, *Senior Director & Head I Asia Discovery lab & CTI I Emerging Science & Innovation, Pfizer*

Professor Jacob George, *Director, Storr Liver Centre at The Westmead Institute for Medical Research, Head, Department of Gastroenterology & Hepatology, Westmead Hospital and Sydney West Local Health District*

Sarah Meibusch, *Principal, One Ventures*

12:55 Networking Lunch

14:00 **PANEL | Getting the Best out of your First in Human Study**

- How to do your first in human study well and efficiently
- How to best allocate resources
- Strategies for having the right data from a pre-clinical perspective
- Ethical considerations
- What are the advantages of bringing your clinical trial into a dedicated phase 1 unit?

Anita Van De Meer, *Manager, Clinical Trials Support Unit | Office for Health and Medical Research, NSW Ministry of Health*

Dr Tina Soulis, *CEO, Neuroscience Trials Australia*

Cameron Johnson, *CEO, Nucleus Network*

Moderator: Karen West, *Executive Director Clinical Development Early Phase, Syneos Health*

14:45 **The Basics of Therapeutic Regulation in Australia**

Avi Rebera, *Assistant Secretary, Regulatory Engagement & Planning Branch, Department of Health (TGA)*

15:15 Networking Break

15:45 **Early Phase Trials for Off-shore Entities: Accessing the R&D Incentive Program**

Jeff Bergmann, *Director, Solubility*

Simone Quin, *Partner, Prime Accounting and Business Advisory Pty Ltd*

16:15 **PANEL | Clinical Trial Recruitment in Australia – From Basics to Best Practice**

- What are the barriers to recruitment?
- Writing a recruitable protocol
- Understanding the challenges and realities in the feasibility stage
- Adequate resourcing and effective connections
- Navigating the challenges of a fragmented health system
- Emerging technologies and innovations to improve clinical trial recruitment in Australia

Leanne Weeks, *Program Director, CT:IQ*

Professor Sabe Sabesan, *Clinical Dean, THHS/JCU Medical Training Director of Medical Oncology, Townsville Cancer Centre, Co-Chair, Australian Teletrial Consortium, Clinical Oncology Society of Australia*

Damien Conti, *Head of Recruitment, Nucleus Network*


Tyron Johnson, *Senior Clinical Development Liaison, Oncology and Diabetes, Eli Lilly Australia and New Zealand*

17:00 **FIRESIDE CHAT | Patient Engagement**

- Effectively engaging patients for early development
- What are the experiences in international markets like the US and Europe?
- How to shape the end points and what's important for the patients
- Success stories in how to get engagement off the ground
- What can the value of effective engagement be?

Nicola Straiton, *Senior Project Officer, Australian Clinical Trials Alliance (ACTA)*

Anne McKenzie, *Manager, Consumer & Community Involvement, Telethon Kids*

17:30 Networking Drinks 

18:30 **BioPalooza Networking Dinner**


8:30 Morning Coffee on Arrival

8:50 **OPENING** | Opening remarks from the Chair

9:00 **KEYNOTE** | **Aussie Success Story: The World's First Minimally Invasive Digital Spinal Cord**

Dr Thomas Oxley, *CEO and Founder, Synchron*

9:30 **INTERNATIONAL KEYNOTE** | **Delivering Treatments for Rare Disease by Drug Repositioning**

 Juran Kato, *President and CEO, GEXVal Inc, Japan*

10:00 **CASE STUDY** | **Building a Strategy and How we Made it Work**

Megan Baldwin, *Managing Director & CEO, Opthea*

10:30 Networking Break

11:00 **CEO PANEL** | **Getting Strategy Right, Raising Capital, Commercialising Effectively**

This session will feature learnings and insights from CEOs on how to strategize on capital raise and further the development of the company, secure institutional investment from overseas and ultimately build the right strategy.

- Raising Capital for Phase 1 Biotechs – Moving to the Next Phase
- Funding opportunities outside the traditional VC / IPO pathways
- Non-dilutive funding opportunities
- Thinking beyond the Australian market – how to drastically improve valuations and growth prospects by looking into scaling overseas

Megan Baldwin, *Managing Director & CEO, Opthea*

Chevlin Lee, *Managing Principal, Chalten Capital*

Gary Phillips, *CEO, Pharmaxis*

Leslie Chong, *MD & CEO, Imugene*

Vishal Doshi, *CEO, AUM Biosciences, Singapore*

11:45 **Translational Science – Driving Productivity & Supporting Innovation**

Dr Ronan Bouër, *Executive Director Clinical Development (Translational Sciences), Syneos Health*

12:15 **PANEL DISCUSSION** | **IP – WHAT is it, WHY do it, WHEN is the right time, HOW do you value it?**

- What can/should be protected by IP, and what commercial value does this provide?
- Identifying and implementing an IP strategy that aligns with your commercialisation strategy (e.g., facilitating licensing, partnerships, spin-out companies)
- How to ensure FTO
- When to file, where to file, sequence of national applications etc
- What IP protection is sought by various commercial partners?
- Unpacking Who Owns the IP in Investigator-Initiated Clinical Trials

Kathy Harrison, *Head of IP Strategy, ProTA Therapeutics*

Damien Bates, *Chief Scientific Officer & Head of Translational Medicine, BioCurate*

Sarah Cox, *Patent & Trade Marks Attorney, Watermark*

13:00 Networking Lunch

14:00 **CASE STUDY** | **Bringing a Platform to the Clinic**

Sam Cobb, *Managing Director & CEO, AdAlta*

14:30 **PANEL** | **Starting with the End in Mind – Getting Commercialisation Right from the Get Go**

A panel of multiple stakeholders to explore how to get your strategy right and the common issues and pitfalls to avoid.

- Understanding the best commercial opportunities for your products
- Understanding what partners are looking for
- Asking the right questions
- How to bring in different perspectives
- Learning to let go

Chris Nave, *Managing Director, Melbourne, Brandon Capital Partners*

Moderator: Jeannie Joughin, *Chief Commercial Advisor, Enable Injections Inc & Independent Commercial Advisor & Consultant*

15:15 **CLOSING PANEL** | **Finding an Industry Partner & Making it Work**

- What are the attributes of a great partner?
- What is pharma looking for and what do they avoid?
- How to make your research stand out from the crowd
- Common behaviours of a collaborating company and researcher – The good and the bad
- How can researchers collaborate with pharma most effectively?
- Which cases work, which don't and why

Brett Roberts, *Head of Strategic Partnerships, Novartis Pharmaceuticals Australia Pty Ltd*

Dr Anand Gautam, *Senior Director & Head I Asia Discovery lab & CTI I Emerging Science & Innovation, Pfizer*

Brett Carter, *Chief Executive Officer, Cancer Therapeutics CRC*

16:00 Close of Conference

### SPONSORSHIP AND EXHIBITION OPPORTUNITIES

Excellent opportunities exist to showcase your organisation.

For further information, please contact:

**Danielle Newman, Sponsorship Manager**

**Phone: (+61) 2 9080 4432**

**Email: [Danielle.Newman@informa.com](mailto:Danielle.Newman@informa.com)**

### VENUE DETAILS

Pullman Melbourne Albert Park, 65 Queens Rd, Albert Park VIC 3004

**Phone: (03) 9529 4300, [www.pullmanalbertpark.com.au](http://www.pullmanalbertpark.com.au)**

# Bio Connections Australia

19 – 20 August 2019 | Pullman Melbourne Albert Park

## Easy Ways to Register

**1 Web**  
[www.informa.com.au/bioconnections2019](http://www.informa.com.au/bioconnections2019)

**2 Telephone**  
+61 (0)2 9080 4307 – Quoting P19A13

**3 Email**  
[info@informa.com.au](mailto:info@informa.com.au) – Quoting P19A13

## Stay Connected



**BioConnectionsAUS**

## Pricing Details

Register Early & Save	Early Bird Rate				Standard Rate		
	Book & pay on or 14 June 2019				Book & pay from 15 June 2019		
Two Day Conference	PRICE	GST	TOTAL	SAVE	PRICE	GST	TOTAL
General Pricing	\$2,395	\$239.50	\$2,634.50	\$400	\$2,795	\$279.50	\$3,074.50
Academia/NFPs/Hospital Rate	\$1,695	\$169.50	\$1,864.50	\$400	\$2,095	\$209.50	\$2,304.50
BioPalooza Dinner (19 Nov 2019)					\$150	\$15	\$165

For full terms and conditions, please visit:

[www.informa.com.au/bioconnections2019](http://www.informa.com.au/bioconnections2019)

If undeliverable return to: PO BOX Q1439, SYDNEY NSW 1230

POSTAGE  
PAID  
AUSTRALIA